Bryan Caudle
Family Medicine · Paradise, CANPI 1992196349
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 100 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 19 manufacturers reported payments, led by AbbVie at 27.5% of the total. 2025 is the largest year on record at $1,210, more than ten times the $35 reported in 2022.
Across 100 payments — averaging $20.44 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$562
- Novo Nordisk$394
- Exact Sciences$142
- Dexcom, Inc.$139
- Medtronic$139
- Pfizer$97
- plus $571 from 13 others
What the payments were for
- Food & beverage$2,044100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 34 | $562 |
| Novo Nordisk | 18 | $394 |
| Exact Sciences | 8 | $142 |
| Dexcom, Inc. | 5 | $139 |
| Medtronic | 1 | $139 |
| Pfizer | 4 | $97 |
| Amgen | 4 | $72 |
| Abbott | 3 | $71 |
| AstraZeneca | 4 | $69 |
| Viatris Specialty LLC | 3 | $55 |
| Kyowa Kirin, Inc. | 2 | $54 |
| Phathom Pharmaceuticals, Inc. | 3 | $48 |
| Otsuka America Pharmaceutical, Inc. | 2 | $48 |
| Lilly USA, LLC | 2 | $39 |
| GSK | 2 | $37 |
| Indivior Inc. | 2 | $33 |
| Insulet Corporation | 1 | $18 |
| Xeris Pharmaceuticals, Inc. | 1 | $14 |
| Boehringer Ingelheim | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- VenaSeal$139
How this compares
$2,044 in reported general payments places this provider in the 80th percentile of 10,533 family medicine providers in California.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| TrulicityDulaglutide | 84 | $80,025 |
| RybelsusSemaglutide | 43 | $79,921 |
| JardianceEmpagliflozin | 79 | $72,890 |
| EliquisApixaban | 55 | $53,787 |
| Breo ElliptaFluticasone/Vilanterol | 114 | $47,246 |
| OzempicSemaglutide | 46 | $46,047 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 16 | $35,858 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 53 | $27,376 |
| JanuviaSitagliptin Phosphate | 27 | $24,485 |
| MounjaroTirzepatide | 16 | $16,228 |
| Novolog FlexpenInsulin Aspart | 27 | $12,752 |
| BelbucaBuprenorphine Hcl | 13 | $12,640 |
| Spiriva RespimatTiotropium Bromide | 18 | $9,304 |
| LinzessLinaclotide | 19 | $8,868 |
| FarxigaDapagliflozin Propanediol | 12 | $8,827 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskRybelsus, Ozempic | $394 | $125,96889 claims |
| Boehringer IngelheimJardiance, Combivent Respimat, Spiriva Respimat, Tradjenta | $14 | $116,856165 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $39 | $96,253100 claims |
| PfizerEliquis | $97 | $53,78755 claims |
| GSKBreo Ellipta, Anoro Ellipta | $37 | $52,346125 claims |
| AbbVieLinzess | $562 | $8,86819 claims |
| AstraZenecaFarxiga | $69 | $8,82712 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 10,533 family medicine providers in California.
Other family medicine in Paradise
- Sherly SoleimanEncino$1.2M
- Pamela KushnerLos Angeles$1.2M
- Sujata NarayanStanford$1.2M
- Jeffrey UngerChino$906K
- Alexander RivkinLos Angeles$866K
- Scott HowellLos Angeles$793K
- Derrick ButlerLos Angeles$692K
- Sandra CalmanMontara$589K
- Anthony JonesOakland$377K
- Amira AyadBakersfield$360K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.